Roche Holding AG RHHVF
470.00 USD -5.00 (-1.05%)
Nov 5, 2026, 3:12 PM EST
470.00 Day range 483.99
324.78 52-week range 499.76
- YTD
- +13.82%
- 1 year
- +45.69%
- Market cap
- 374.48B
- EPS (ttm)
- 19.32
- P/E ratio
- 24.33
- YTD return
- +13.82%
- 1-year return
- +45.69%
- Volume
- 21
- Avg volume
- 3.48K
- Open
- 483.99
- Previous close
- 475.00
- Day's range
- 470.00 – 483.99
- 52-week range
- 324.78 – 499.76
- Earnings date
- Feb 4, 2027
5D -20.00 (-4.08%)
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 11.88.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 11.88 | — | — | — |
| Jul 23, 2026 | Jun 30, 2026 | 12.51 | 13.42 | +0.91 | +7.27% |
| Jan 29, 2026 | Dec 31, 2025 | 10.83 | 10.56 | -0.27 | -2.49% |
| Jul 24, 2025 | Jun 30, 2025 | 13.18 | 13.97 | +0.79 | +5.99% |
| Jan 30, 2025 | Dec 31, 2024 | 9.25 | 9.44 | +0.19 | +2.05% |
| Jul 22, 2024 | Jun 30, 2024 | 10.42 | 11.38 | +0.96 | +9.21% |
News
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs 
Roche: Valuation Leaves Limited Upside 
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors 
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug 
Roche says divarasib cut risk of death 44% in lung cancer trial 
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer 
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer 
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN) 
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) 
Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript
Your note
Sign in to keep a note on RHHVF — it syncs with the Stock Master app.